Tim Carmichael (@TimCarmichael3) profile picture

Living the dream. No free lunch on Wall Street.

Monmouth Beach, NJ/Jupiter,FL
Joined October 2012
Photo by Tim Carmichael (@TimCarmichael3)Photo by Tim Carmichael (@TimCarmichael3)Photo by Tim Carmichael (@TimCarmichael3)Photo by Tim Carmichael (@TimCarmichael3)
Tim Carmichael retweeted
Less than a year ago, DOGE cut 400 jobs at the already understaffed FAA. At the time, FAA employees said the cuts would "have long-term safety implications." Looks like they were right. apnews.com/article/faa-firin…
798
4,095
183
10,918
194,855
Tim Carmichael retweeted
$ORCL just laid out a pretty wild FY2029 FCF target of over $30B versus expectations just ~$6B. Also awesome to hear Oracle plans to raise no more than $20B in new debt and equity through FY2030 which directly addresses concerns about how it will fund its massive AI buildout.
$ORCL just laid out a path to $225B in revenue by FY2030 which would triple its business in 4 years. Even more interesting is that Oracle expects its growth to be self-funded by FY2029 which could ease concerns about how much debt it needs to finance its massive AI buildout.
26
34
6
318
54,276
BREAKING: Oracle stock, $ORCL, surges over +12% after announcing expectations that free cash flow will reach $30 billion in FY2029. Investors had expected free cash flow to remain negative in that year. The company is also guiding for $225 billion in revenue by FY2030.
219
298
91
3,385
429,047
Tim Carmichael retweeted
$TGTX AZER CEL does not disappoint- 89% of evaluable participants (16/19) had stable or improved disability scores at Day 90, despite documented progression prior to enrollment on high-efficacy therapies
4
9
2
31
12,812
Tim Carmichael retweeted
$AZN busy newsflow with multiple positive readouts and approvals on October 22, led by accelerated FDA approval for Ultomiris in IgA nephropathy and the U.S. launch of Zegfrovy for targeted lung cancer. The company also added positive Phase III evidence for Tezspire in eosinophilic esophagitis, reinforcing momentum across oncology and immunology.
$AZN Bofa Pipeline deep dive: $30bn peak sales; first look into busy FY27 - BUY 75page pipeline deep dive with first look into busy FY27 path. c$11bn peak sales 2H26, c$19bn in FY27; >20% upside to cons Data offers upside to FY30 $80bn sales guide (could be >$100bn) and visibility on growth post 2030 through patent cliff Biopharma PIII is high probability, in substantial markets and under-appreciated. Oncology PIIIs also big but riskier
1
1
2,865
Tim Carmichael retweeted
$ABVX Piper PT $175 While ABVX shares have struggled of late for a variety of reasons, continue to believe in the fundamental value of obe as a highly differentiated treatment option in IBD, a view strengthened by the UEGW data, &continue to believe shares are undervalued at current levels. Remain buyers. Subgroup analyses extend obefazimod’s efficacy findings to additional endoscopic endpoints.
$ABVX MS PT $180 UEG meeting highlight consistent longer term durability and meaningful benefits across maintenance subgroups, further supporting the broad potential of obefazimod in ulcerative colitis (UC) ahead of regulatory filing expected by YE26.
1
2
1
36
11,780
Tim Carmichael retweeted
$ABVX Buy) TRUIST With durability holding, the discussion increasingly turns to where obe' fits and how broadly it could be used. From our discussions at UEG, we sense KOL focus has shifted from parsing efficacy to earlier vs. later-line use, the place for an oral, and whether obe' could serve as a monotherapy backbone or combination partner
4
4
47
6,773
Tim Carmichael retweeted
$CYTK BRiley Buy; $146.00 PT) 30% off 52-wk highs on nHCM safety scare the HFSA data just defused, i.e., events early, AF-driven, label-addressable. IQVIA sales doubled QoQ; Street at $38M looks stale. Only CMI with a positive nHCM Ph3; $EWTX is uncontrolled and years behind. Four catalysts in six weeks, i.e., 3Q print, MAPLE PDUFA 11/14, nHCM filing, AMBER-HFpEF.
1
6
1
18
5,362
Tim Carmichael retweeted
$VKTX RJ points out just what $VKTX has going for it Viking now has two PIVOTAL programs (oral &subQ) in its obesity platform along with a clinical-stage amylin agonist & an ongoing maintenance dosing program (oral &subQ), which we think gives it a very competitive position in the EXTREMELY LARGE #obesity market.
$VKTX reminder just of what Ph2 showed up to 12.2% mean weight loss at 13 weeks without plateau, with doses >15mg demonstrating statistically significant reductions vs. placebo.
3
4
42
4,958
Tim Carmichael retweeted
UBS⬇️ $CYTK's PT to $104, reiterated Buy and said -- We see CYTK as an attractive launch name (oHCM) that has the added benefit of diversification (nHCM) and potential removal of competitive overhang (EWTX). $EWTX $BMY TECX TENX AZN NVO BAAYRY UBS added—Similar to a number of other commercial biotech names (NBIX, AXSM, JAZZ, UTHR, INSM), CYTK has also underperformed recently as XBI pulled back. However, if interest-rate hike cycle is likely to drive further "risk-off" environment, we believe names like CYTK can outperform from current levels. In our view, Myqorzo will see continued sales inflection in 3Q which could point towards strong FY26/27 sales. Along with oHCM launch updates, we see multiple potentially positive catalysts on the horizon: 1) nHCM SNDA submission, 2) EDG-7500 Ph3 trial initiation (requiring echos); and 3) MAPLE/1L label expansion (PDUFA Nov. 14). We lower our PT to $104 (from $115), and reit our Buy rating.
Cantor reiterated an Overweight rating on $CYTK after its fireside chat w/ mgmt. $EWTX $BMY TECX TENC AZN NVO BAYRY Cantor said in its note: Management reiterated its expectation for ~50% NBRx share by year-end, with paid prescription share likely settling around ~80-85% longer term. Real-world titration has been flexible, with only a minority of prescribers titrating Q2W and many using Q6W-Q8W intervals around patient schedules such as holidays. Longer term, management continues to see a path toward relaxing or potentially removing REMS, though this will likely require a multi-year process with a larger body of real-world evidence. Beyond oHCM/nHCM, earlier-course use and at-risk patients remain potential expansion opportunities for aficamten. Ex-US Expectations and Guideline Inclusion. Management expects physician behavior in Europe to broadly resemble the US. HCM guidelines are also expected to be revised in 2027, and management believes ACACIA should be referenced even if guideline publication precedes nHCM approval. Despite encouraging MAPLE data, management's base case remains that CMIs are unlikely to displace beta-blockers as front-line therapy in the next guideline update, given the broader community is still early in adoption.
2
1
5
2,950
Tim Carmichael retweeted
$CTMX Cantor Overweight, Target: $12.00) Varseta-M YE26 Data Could Be a Confidence Catalyst Ahead of Phase 3
2
3
2
21
5,621
Tim Carmichael retweeted
$TGTX BRIUMVI was associated with a lower risk of 24-week confirmed disability progression and lower annualized relapse rates (ARRs) over five years compared with ocrelizumab and ofatumumab Highlights Five-year anti-CD20 outcomes were compared using an unanchored MAIC.

•
Ublituximab showed consistently low relapse rates throughout five years.

•
Ublituximab was associated with lower CDP24 risk than both comparators.

•
Ublituximab yielded 8–13 more weeks free from progression over 240 weeks.
1
7
33
4,109
Tim Carmichael retweeted
$TGTX 5 year data now that simply shows what social media been telling us awhile now #Briumvi is better then #Ocrevus & #ofatumumab
$TGTX been seeing it on social media awhile now - but great here from leaders BRIUMVI is Just better CD20 for MS - suboptimal experience on prior anti-CD20 therapies who have seen improvements on BRIUMVI.
4
38
4,385
Tim Carmichael retweeted
$VKTX OPPY Ph3 SUNRISE study designs indicate maximum doses of only 55mg will be evaluated. view this update as a meaningful positive surprise. believe VK2735's oral obesity opportunity has now been substantially derisked.
$VKTX ole my - what work you do @Mufaso7 hammer drop by VK2735 - thank you
2
5
1
51
14,330
Tim Carmichael retweeted
BRILEY Top Picks ahead of 3Q26 Earnings $AXSM $CYTK $ETON $HROW $TGTX $ZYME.
1
2
1
19
13,519
Tim Carmichael retweeted
So, uhh.... $QURE is still getting approved, isn't it? 👉The 4 year data from today isn't even part of the accelerated approval data package that was submitted to the FDA. Accelerated approval submission was on 3 year data. 👉The 3 year data with newly added patients got *even better* on cUHDRS delta. 👉The accelerated approval endpoint is cUHDRS at 3 years, but the confirmatory trial endpoint will be TFC. The new 4 year data that people are freaking out about today missed stat sig on cUHDRS, but *is still stat sig on TFC*, which again, will be the actual confirmatory trial endpoint. 👉"There is no placebo group" people always ignore the low dose cohort too. Why? Patients were blinded to dose cohort, making the low dose cohort essentially a placebo cohort with a 10x lower dose. The high dose is *still stat sig superior to the low dose group* at 48 months on both endpoints versus this "pseudo placebo" group. 👉CSF NfL is totally flat after 4 years, whereas it should be up *significantly* in untreated HD patients. All of the above points will be discussed at the ADCOMM, which was already expected before today's data. The FDA refusing to approve this would sincerely surprise me. "But what about commercial viability?!" Do you even know what we are talking about here? This is Huntington's disease...You think nobody is going to want the drug because "The 4 year ~50% reduction of disease slightly missed statistical significance against the external control!" Patients will see ~50% slowing on cUHDRS (missed stat sig) and ~60% slowing on TFC (strongly stat sig) and want the drug. This part is not complicated. The only question was and is: Approval or no approval? You think the current FDA is gonna reject this? LOL, ok - let's see.
38
31
20
333
95,403
Tim Carmichael retweeted
$VKTX Truist $83 pt Truist analyst Gregory Renza says Viking Therapeutics' VK2735 obesity data this morning represents a "best-case scenario." Induction came in at 17.8% on 17.5 mg, with the exploratory continued-weekly cohort running to 21.7% by week 33 and still showing no plateau, the analyst tells investors in a research note. Truist says the readout "clears our bar, drawing a healthy balance of inbounds with the data a point of interest among a dense obesity landscape." VK2735's tolerability "came in clean," which "de-risks the step-down construct," the firm adds. It maintains a Buy rating on Viking Therapeutics with an $83 price target. The stock in morning trading is up 22% to $36.86.
5
1
15
10,815